Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) presented additional Phase 2 pilavapadin data for diabetic peripheral neuropathic pain (DPNP) on Oct 14, 2025. Analyses support advancing a 10 mg once-daily dose into Phase 3 and a U.S. FDA end-of-Phase 2 meeting request has been accepted.
The pooled post-hoc analysis covered >600 patients from RELIEF-DPN 1 and PROGRESS, reported a 2-point average daily pain score (ADPS) reduction at 12 weeks for 10 mg, showed a linear exposure-response relationship, found an acceptable safety and tolerability profile, and noted lower adherence and increased tolerability symptoms in the PROGRESS 20 mg arm. A slide deck is available on the company events page.
Positive
- End-of-Phase 2 meeting request accepted by FDA
- Pooled enrollment >600 patients across Phase 2 studies
- 2-point ADPS reduction from baseline at 12 weeks for 10 mg
- Linear exposure-response relationship supporting 10 mg
- Safety/tolerability profile comparable to placebo
Negative
- 20 mg arm showed lack of efficacy in PROGRESS
- Lower adherence in 20 mg participants tied to tolerability
News Market Reaction
On the day this news was published, LXRX gained 1.39%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $523M at that time.
Data tracked by StockTitan Argus on the day of publication.
– Results support advancement of 10 mg dose into Phase 3 development –
– End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing –
THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit.
These data follow the topline results from the Phase 2b PROGRESS study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) announced in March of 2025, which identified 10 mg once daily as the most clinically meaningful and appropriate dose to advance into Phase 3 development.
“Following the release of topline results from our PROGRESS study earlier this year, we performed additional analyses of the Phase 2 program data that support Phase 3 readiness of the 10mg dose of pilavapadin for DPNP. With these additional analyses, we have submitted an end-of-Phase 2 meeting with the U.S. FDA,” said Mike Exton, Ph.D., chief executive officer and director of Lexicon. “Our request has been accepted by the FDA and, in tandem, we are actively progressing discussions with potential partners.”
The additional analyses from the Phase 2 program resulted in four primary conclusions by the company with respect to the 10mg dose of pilavapadin:
- Validated biological activity, as evidenced by a linear relationship between increased plasma levels of pilavapadin and pain reduction.
- Clinically meaningful efficacy, with a 2-point average daily pain score (ADPS) reduction from baseline at 12 weeks.
- Acceptable tolerability profile, with placebo-like treatment completion rates.
- Acceptable safety profile in line with standard of care, further bolstered by subsequent studies showing no prolonged QTc interval with pilavapadin treatment and no significant impact on the pharmacokinetics (PK) of pilavapadin from mild to moderately impaired renal function.
The data presentation included results from a post-hoc, pooled analysis of the Phase 2 RELIEF-DPN 1 and Phase 2b PROGRESS studies, which collectively enrolled more than 600 patients, designed to investigate the exposure-response relationship across the two Phase 2 studies, investigate the lack of efficacy of the 20 mg dose in the PROGRESS study, and confirm the robustness of the 10 mg dose for Phase 3 studies. Participants in the PROGRESS 20 mg dose arm were less adherent than participants in the other study arms, potentially driven by increased tolerability symptoms among patients receiving the 20mg dose and potentially driving the lack of observed dose response in that arm.
The slide presentation from the 19th Annual Pain Therapeutics Summit is available on the Events page of the Company’s website at https://investors.lexpharma.com/.
About Pilavapadin
Discovered using Lexicon’s unique approach to gene science, pilavapadin (LX9211) is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target for neuropathic pain which inhibits reuptake and recycling of neurotransmitters involved in pain signaling without affecting opiate pathways. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of pilavapadin demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What did Lexicon (LXRX) announce about pilavapadin on October 14, 2025?
Why is Lexicon advancing the 10 mg pilavapadin dose to Phase 3 (LXRX)?
What safety and tolerability findings did Lexicon report for pilavapadin (LXRX)?
What issue was observed with the 20 mg pilavapadin dose in the PROGRESS study (LXRX)?
Has Lexicon secured FDA alignment for pilavapadin Phase 3 design (LXRX)?
Where can investors find the pilavapadin presentation from Oct 14, 2025 (LXRX)?
